Rockville, MD — October 22, 2025
Xcellon Biologics, an Antibody Drug Conjugate (ADC) CDMO, announced a new collaboration with Invenra Inc. to accelerate multispecific ADC programs. The partnership combines Invenra’s discovery platforms with Xcellon’s expertise in bioconjugation, process development, and GMP-ready manufacturing. Together, the companies aim to advance the next generation of targeted therapeutics.
Read the full press release on Business Wire.
Under this collaboration, Invenra will apply its proprietary B Body bispecific and T Body trispecific technologies to design antibody formats that improve tumor targeting and potency. Meanwhile, Xcellon Biologics will provide ADC process development, analytical support, and scale-up through its integrated platform designed for preclinical and clinical readiness.
“We are excited to partner with Invenra, a leader in multispecific antibody engineering,” said Yuk Chun Chiu, Chief Operating Officer of Xcellon Biologics. “Together we can translate scientific innovation into reliable, scalable therapeutics for patients.”
Moreover, this collaboration builds on Xcellon’s recent funding support and reinforces its mission to strengthen Maryland’s biomanufacturing ecosystem. As an Antibody Drug Conjugate CDMO, Xcellon supports sponsors from candidate assessment to IND-enabling studies. The company focuses on linker–payload selection, conjugation strategies, and developability risk reduction to ensure strong manufacturability.
In addition, the platform emphasizes clear CQA definition, robust downstream purification, and fit-for-purpose stability programs. These elements collectively help ease the transition into GMP manufacturing. By aligning discovery with manufacturability early, the team shortens development timelines without compromising quality. Consequently, this approach positions Xcellon as a leading Antibody Drug Conjugate CDMO for complex ADC programs.
Explore related capabilities and company information:
Xcellon Biologics and Invenra announce a new ADC collaboration
